Pulmonary vascular disease & thromboembolism
Pulmonary Artery Denervation Versus Conventional Therapies for PAH: A Systematic Review and Updated Network Meta-Analysis
Authors' conclusion
Compared with 16 types of conventional therapies and Placebo, PADN has advantage over nine single therapies and Placebo in improving 6MWD and appears to be better than two types of dual-drug combined therapies while with no statistical significance. PADN shows a favourable antihypertensive effect on mPAP and has a lower risk to trigger clinical worsening or hospitalization, while its risk on mortality and severe adverse events is still inconclusive.
Study context
- Population
- Pulmonary arterial hypertension65 randomized controlled trials (RCTs)
- Comparison
- Pulmonary artery denervation (PADN) vs conventional PAH therapies and placebo
- Outcome
- Change in 6MWD from baseline
Methodological detailsPRISMA
- PRISMA
Pooled result
As reported in the abstract
Further pooled results
Change in mean pulmonary artery pressure (mPAP)
- PADN better antihypertensive effect than placebo
Mortality and severe adverse events (SAEs)
- No statistically significant difference between PADN and other interventions
Safety
Clinical worsening and re-hospitalization
- PADN significantly lower risk than treprostinil, riociguat and placebo
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →